BDTX - Black Diamond Therapeutics Inc Stock Price, Fair Value and News

$2.67-0.78 (-22.61%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BDTX Price Action

Last 7 days

-29.4%

Last 30 days

-32.4%

Last 90 days

-7.0%

Trailing 12 Months

8.1%

BDTX RSI Chart

BDTX Valuation

Market Cap

152.1M

Price/Earnings (Trailing)

7.08

Price/Sales (Trailing)

130.1

Price/Free Cashflow

7.13

BDTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BDTX Fundamentals

BDTX Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

BDTX Earnings

Earnings (TTM)

21.5M

Earnings Growth (Yr)

45.38%

Earnings Growth (Qtr)

19.53%

BDTX Profitability

Return on Equity

17.04%

Return on Assets

13.63%

Free Cashflow Yield

14.03%

BDTX Investor Care

Shares Dilution (1Y)

0.69%

Diluted EPS (TTM)

0.36

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	1.8M	1.7M	0
2023	2.3M	2.4M	2.3M	1.9M
2022	2.7M	0	2.3M	2.2M
2021	4.4M	4.5M	4.1M	3.5M
2020	1.2M	2.1M	3.2M	4.0M
2019	0	0	0	461.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Black Diamond Therapeutics Inc

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. David M. Epstein Ph.D.
WEBSITE	blackdiamondtherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	65

Black Diamond Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Black Diamond Therapeutics Inc? What does BDTX stand for in stocks?

BDTX is the stock ticker symbol of Black Diamond Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Black Diamond Therapeutics Inc (BDTX)?

As of Wed Dec 03 2025, market cap of Black Diamond Therapeutics Inc is 152.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BDTX stock?

You can check BDTX's fair value in chart for subscribers.

Is Black Diamond Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BDTX is over valued or under valued. Whether Black Diamond Therapeutics Inc is cheap or expensive depends on the assumptions which impact Black Diamond Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BDTX.

What is Black Diamond Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, BDTX's PE ratio (Price to Earnings) is 7.08 and Price to Sales (PS) ratio is 130.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BDTX PE ratio will change depending on the future growth rate expectations of investors.